Search results for " monoclonal"

showing 10 items of 807 documents

Incidence of lineage promiscuity in acute myeloblastic leukemia: Diagnostic implications of immunoglobulin and T-cell receptor gene rearrangement ana…

1988

Abstract Sixty-nine blood or bone marrow samples from both children and adults with acute myeloblastic leukemia (AML) were investigated to elucidate the frequency of immunoglobulin (IG) and T-cell receptor (TCR)-gene rearrangements. Non-germline configuration for the IG heavy chain (h) gene was detected in the specimens of nine patients of various subtypes according to the French-American-British classification (FAB), including FAB M1, M2, M4 and M5. Rearrangement of the IG kappa chain (k) gene was present in one of these cases which simultaneously revealed a rearranged TCR-beta (b) chain gene. In another two AML samples we found TCR-b gene rearrangements, in one case in combination with an…

AdultImmunoglobulin geneCancer ResearchAcute myeloblastic leukemiaCD19medicineHumansGene Rearrangement beta-Chain T-Cell Antigen ReceptorChildGenes ImmunoglobulinbiologyAntibodies MonoclonalCell DifferentiationHematologyGene rearrangementmedicine.diseaseMolecular biologyLeukemia Myeloid AcuteLeukemiaPhenotypeOncologyTerminal deoxynucleotidyl transferaseT-Cell Receptor Genebiology.proteinAntibodyImmunoglobulin Heavy ChainsLeukemia Research
researchProduct

Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis.

2004

Objective— Functionally interactive proteases of the plasminogen/plasmin and the matrix metalloproteinase (MMP) system degrade and reorganize the extracellular matrix of the vessel wall in atherosclerosis. Here we investigated whether such proteases are able to confer atherogenic properties onto low density lipoprotein by nonoxidative modification. Methods and Results— Similar to the recently described enzymatically-modified low-density lipoprotein (E-LDL), native LDL exposed to plasmin or matrix MMP-2 or MMP-9 and cholesterylester-hydrolase (CEH) showed extensive deesterification, with ratios of free cholesterol to total cholesterol rising to 0.8 compared with 0.2 in native LDL. When the …

AdultLipoprotein modificationProteasesAdolescentPlasminArteriosclerosisBlotting WesternMatrix metalloproteinaseComplement Hemolytic Activity AssayMonocyteschemistry.chemical_compoundmedicineHumansTrypsinFibrinolysinComplement ActivationCells CulturedAgedbiologyMacrophagesAntibodies MonoclonalSodium Dodecyl SulfateLipoprotein(a)Middle AgedSterol EsteraseCell biologyLipoproteins LDLC-Reactive ProteinchemistryBiochemistryMatrix Metalloproteinase 9Low-density lipoproteinbiology.proteinMatrix Metalloproteinase 2lipids (amino acids peptides and proteins)Electrophoresis Polyacrylamide GelCardiology and Cardiovascular MedicinePlasminogen activatormedicine.drugLipoproteinArteriosclerosis, thrombosis, and vascular biology
researchProduct

Spontaneous Monokine Release by Alveolar Macrophages in Chronic Sarcoidosis

1991

In pulmonary sarcoidosis an activation of alveolar T lymphocytes and alveolar macrophages (AM) has been demonstrated. There is evidence that in contrast to acute disease a heightened T-cell response cannot be observed in the chronic phase of sarcoidosis. The role of AM in the inflammatory process of chronic sarcoidosis is not yet intensively evaluated. To address this question we measured the release of tumor necrosis factor alpha (TNFα) and interleukin-1 (IL-1) by AM of 39 patients with chronic sarcoidosis (duration > 4 years; 30 active, 9 inactive diseases) without therapy and correlated the monokine release with parameters of T-cell alveolitis and the course of the disease. The T4/T8 …

AdultLung DiseasesMaleSarcoidosisT-Lymphocytesmedicine.medical_treatmentImmunologyCD4-CD8 Ratio610 MedizinBronchoalveolar Lavage Fluid/immunologyTumor Necrosis Factor-alpha/biosynthesisLymphocyte Activation/immunologyLymphocyte ActivationMacrophages AlveolarmedicineHumansImmunology and AllergyMacrophageAntibodies Monoclonal/immunologyInterleukin-1/biosynthesisddc:610Tumor Necrosis Factor-alphabusiness.industryRespiratory diseaseAntibodies MonoclonalInterleukinGeneral MedicineT-Lymphocytes/immunologymedicine.diseaseSarcoidosis/immunologyMonokineLung Diseases/immunologyCytokinemedicine.anatomical_structureChronic DiseaseImmunologyMacrophages Alveolar/immunologyFemaleTumor necrosis factor alphaSarcoidosisPulmonary alveolusbusinessBronchoalveolar Lavage FluidInterleukin-1International Archives of Allergy and Immunology
researchProduct

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3…

2016

Abstract Purpose: A first-in-human phase I study was conducted to characterize safety, efficacy, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of lumretuzumab, a humanized and glycoengineered anti-HER3 monoclonal antibody, in patients with advanced cancer. Experimental Design: Twenty-five patients with histologically confirmed HER3-expressing tumors received lumretuzumab (100, 200, 400, 800, 1,600, and 2,000 mg) every two weeks (q2w) in 3+3 dose-escalation phase. In addition, 22 patients were enrolled into an extension cohort at 2,000 mg q2w. Results: There were no dose-limiting toxicities. Common adverse events (any grade) included diarrhea (22 patients, 46.8%), fatigue (21 …

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyPathologyMaximum Tolerated DoseReceptor ErbB-3CmaxAntibodies Monoclonal HumanizedResearch SupportGastroenterologyClinical Trial Phase I03 medical and health sciencesPhase I0302 clinical medicinePharmacokineticsInternal medicineJournal ArticlemedicineHumansNon-U.S. Gov'tAdverse effectAgedAnalgesicsbusiness.industryResearch Support Non-U.S. Gov'tCancerMiddle AgedLumretuzumabmedicine.diseaseClinical TrialMulticenter StudyTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisPharmacodynamicsMonoclonalFemaleColorectal NeoplasmsbusinessEx vivo
researchProduct

Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma

2018

Long-term oral corticosteroid (OCS) use in patients with severe asthma is associated with significant adverse effects.This 40-week, randomised, double-blind trial evaluated the OCS-sparing potential of tralokinumab in patients with severe, uncontrolled asthma requiring maintenance OCS treatment plus inhaled corticosteroids/long-acting β2-agonists. Overall, 140 patients were randomised to tralokinumab 300 mg or placebo (n=70 in each group) administered subcutaneously every 2 weeks. The primary end-point was percentage change from baseline in average OCS dose at week 40, while maintaining asthma control. Secondary end-points included proportion of patients with a prescribed maintenance OCS do…

AdultMale0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classAdministration OralPlacebolaw.invention03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled trialAdrenal Cortex HormoneslawInternal medicineAdministration InhalationmedicineHumansAnti-Asthmatic AgentsAdverse effectAgedInhalationRespiratory tract infectionsbusiness.industryAntibodies MonoclonalMiddle AgedAsthmaClinical trialTreatment Outcome030104 developmental biology030228 respiratory systemDisease ProgressionCorticosteroidFemalebusinessTralokinumabEuropean Respiratory Journal
researchProduct

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.

2020

Background: Current availability of several biologic treatments for severe asthma makes it possible to choose the most appropriate for each patient. Sometimes a good percentage of patients with severe asthma may be eligible for biologics that target either the allergic phenotype or the eosinophilic one, but not all respond to that selected as first choice. The aim of our real-life study was to assess whether, for patients with severe eosinophilic allergic asthma, not previously controlled by the anti-IgE omalizumab, the shift to another biologic targeting interleukin-5, such as mepolizumab, may represent a good therapeutic choice. Methods: A total of 41 consecutive patients with severe, per…

AdultMale0301 basic medicinePulmonary and Respiratory Medicinesevere asthmamedicine.medical_specialtyTime FactorsSevere asthmamepolizumab omalizumab severe asthma switchingOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioAntibodies Monoclonal HumanizedSeverity of Illness Index03 medical and health sciences0302 clinical medicinereal lifeAnti-Allergic AgentsHumansMedicineswitching.Pharmacology (medical)Anti-Asthmatic AgentsPulmonary EosinophiliaIntensive care medicineLungOriginal ResearchAgedRetrospective Studieslcsh:RC705-779switchingDrug Substitutionbusiness.industrymepolizumablcsh:Diseases of the respiratory systemMiddle AgedAsthmaTreatment Outcome030104 developmental biologyItaly030228 respiratory systemomalizumabFemalebusinessMepolizumabmedicine.drug
researchProduct

Autoreactive liver-infiltrating T cells in primary biliary cirrhosis recognize inner mitochondrial epitopes and the pyruvate dehydrogenase complex.

1993

Primary biliary cirrhosis (PBC) is characterized by lymphoid infiltrates in the portal tracts of the liver and the occurrence of antimitochondrial autoantibodies in serum directed against components of the pyruvate dehydrogenase complex and the other alpha-keto acid dehydrogenase complexes. These enzymes are located on the inner mitochondrial membrane. The destruction of the biliary tract in PBC is thought to be mediated by autoreactive liver-infiltrating T cells exerting cytotoxic activity or releasing certain lymphokines. In this study the reactivity of liver infiltrating T cells was shown to a bovine pyruvate dehydrogenase complex (PDH), a purified E2 subunit (PDH-E2) and a crude prepara…

AdultMaleAdolescentBiliary cirrhosisT-LymphocytesEnzyme-Linked Immunosorbent AssayMitochondria LiverPyruvate Dehydrogenase ComplexAutoimmune hepatitisEpitopesPrimary biliary cirrhosisCell MovementmedicineCytotoxic T cellHumansCells CulturedAgedAutoantibodiesHepatologybiologyLiver Cirrhosis BiliaryAntibodies MonoclonalMiddle Agedmedicine.diseasePyruvate dehydrogenase complexPhenotypeLiverImmunologybiology.proteinFemaleAntibodyViral hepatitisCD8Journal of hepatology
researchProduct

Both IL-12p70 and IL-23 are synthesized during active Crohnʼs disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody

2005

Background: Interleukin (IL)-12p70 and IL-23 are key T helper-1 (TH1) cytokines that drive the inflammation seen in numerous models of intestinal inflammation. These molecules contain an identical p40 chain that is bound to a p35 chain in IL-12 and a p19 chain in IL-23, making both potentially susceptible to modulation by an anti-IL-12p40 monoclonal antibody (mAb). Methods: In the present study, we sought to determine whether active inflammation in Crohn's disease (CD) is associated with the increased synthesis of both of these cytokines and whether patients treated with an anti-IL-12p40 mAb down-regulate IL-23 as well as IL-12p70 as previous reported. Results: To this end we initially dete…

AdultMaleAdolescentBiopsyT-Lymphocytesmedicine.medical_treatmentT cellDown-RegulationInterleukin-23Crohn DiseaseInterleukin 23medicineHumansImmunology and AllergyCells CulturedAgedLamina propriaMucous MembraneCD40biologyInterleukin-12 Subunit p40Interleukin-6InterleukinsMacrophagesGastroenterologyAntibodies MonoclonalInterleukinMiddle AgedInterleukin-12Protein Subunitsmedicine.anatomical_structureCytokineImmunologyInterleukin-23 Subunit p19biology.proteinInterleukin 12FemaleTumor necrosis factor alphaInterleukin-1Inflammatory Bowel Diseases
researchProduct

Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics

2002

Background: Antibodies to soluble liver antigen/liver pancreas (SLA/LP) are specific markers of autoimmune hepatitis. Their target antigen has recently been cloned. Aims: To establish standardised immunoassays using the recombinant antigen, and to assess the frequency and significance of seropositivity in patients from different countries. Methods: An enzyme linked immunoassay was developed using purified recombinant antigen and validated by testing sera from 200 healthy blood donors and 1026 patients with various liver and non-liver diseases. The assay was then applied to 454 sera from 419 patients with autoimmune hepatitis from different countries. All sera were also tested by inhibition …

AdultMaleAdolescentEnzyme-Linked Immunosorbent AssayAutoimmune hepatitisSensitivity and Specificitylaw.inventionJapanMaintenance therapyAntigenRecurrencelawGermanymedicineHumansChildAutoimmune diseaseHepatitisbiologymedicine.diagnostic_testbusiness.industryLiver DiseasefungiHistocompatibility Antigens Class IHistocompatibility Antigens Class IIInfant NewbornGastroenterologyAntibodies MonoclonalInfantmedicine.diseaseRecombinant ProteinsUnited StatesHepatitis AutoimmuneTreatment OutcomeChild PreschoolImmunoassayImmunologybiology.proteinRecombinant DNAFemaleAntibodybusinessBiomarkersBrazilGut
researchProduct

Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical hodgkin lymphoma and correlation with early FDG-PET a…

2017

In Hodgkin Lymphoma (HL), about 20% of patients still have relapsed/refractory disease and late toxic effects rate continue to rise with time. 'Early FDG-PET' and tissue macrophage infiltration (TAM) emerged as powerful prognostic predictors. The primary endpoint was to investigate the prognostic role of both early FDG-PET and TAM; the secondary endpoint was to test if early FDG-PET positivity could correlate with high TAM score. A cohort of 200 HL patients was analysed. Induction treatment plan consisted of two to six courses of ABVD and, if indicated, involved field radiation therapy. All patients repeated CT scan and FDG-PET after two cycles and after the completion of therapy. TAM in di…

AdultMaleAdolescentHodgkin’s lymphomaMacrophagePrognosiAntigens Differentiation MyelomonocyticVinblastineDisease-Free SurvivalCohort StudiesBleomycinYoung AdultAntigens CDFluorodeoxyglucose F18RecurrencePositron Emission Tomography Computed TomographyAntineoplastic Combined Chemotherapy ProtocolsHumansCD68AgedAged 80 and overHodgkin's lymphomahematologyMacrophagesCD68; Hodgkin's lymphoma; macrophages; PET; prognosis; hematology; oncology; cancer researchAntibodies MonoclonalMiddle AgedPrognosisHodgkin DiseaseImmunohistochemistryDacarbazineTreatment OutcomePETDoxorubicinPositron-Emission Tomographyoncologycancer researchFemaleNeoplasm Recurrence LocalFollow-Up Studies
researchProduct